Norditropin^® – dosing of adult patients¹

The following dosing recommendations for Norditropin^® are described in the Norditropin^® Prescribing Information. Please refer to the Norditropin^® Prescribing Information for further details.

Prescribing Information

Norditropin^® adult dosing recommendations

Norditropin^® should be administered subcutaneously. Therapy with Norditropin^® should be supervised by a physician who is experienced in the diagnosis and management of adult patients with either childhood onset or adult onset growth hormone deficiency (GHD).

Body weight-based dosing
Based on the weight-based dosing utilized in the clinical studies, the recommended dosage at the start of therapy is not more than 0.004 mg/kg/d. The dose may be increased to not more than 0.016 mg/kg/d after approximately six weeks according to individual patient requirements. Clinical response, side effects, and determination of age- and gender-adjusted serum IGF-I levels may be used as guidance in dose titration.

Individualized dosing
Alternatively, taking into account recent literature, a starting dose of approximately 0.2 mg/d (range, 0.15-0.30 mg/d) may be used without consideration of body weight. This dose can be increased gradually every one to two months by increments of approximately 0.1-0.2 mg/d, according to individual patient requirements based on the clinical response and serum IGF-I concentrations. During therapy, the dose should be decreased if required by the occurrence of adverse events and/or serum IGF-I levels above the age- and gender-specific normal range. Maintenance dosages vary considerably from person to person.

Special populations
A lower starting dose and smaller dose increments should be considered for older patients, who are more prone to the adverse effects of somatropin than younger individuals. In addition, obese individuals are more likely to manifest adverse effects when treated with a weight-based regimen. To reach the defined treatment goal, estrogen-replete women may need higher doses than men. Oral estrogen administration may increase the dose requirements in women.

Preparation and administration

Convenient delivery devices provide ease of use for the patient. FlexPro^® is prefilled and preloaded with the medication and the selected dose is injected with the touch of a button.

Instructions for administering Norditropin^® with FlexPro 5 mg/1.5 mL, 10 mg/1.5 mL and 15 mg/1.5 mL pens are provided in the Patient Information and Instructions for Use leaflets enclosed with the NordiFlex^™ prefilled pen.

Click here for the FlexPro^® 5 mg/1.5 mL Instructions for Use.
Click here for the FlexPro^® 10 mg/1.5 mL Instructions for Use.
Click here for the FlexPro^® 15 mg/1.5 mL Instructions for Use.

Instructions for delivering the dosage with NordiFlex^™ 5 mg/1.5 mL, 10 mg/1.5 mL, 15 mg/1.5 mL, and 30 mg/3 mL pens are provided in the Patient Information and Instructions for Use leaflets enclosed with the NordiFlex^™ prefilled pen.

Click here for the Norditropin NordiFlex^® 5 mg/1.5 mL Instructions for Use.
Click here for the Norditropin NordiFlex^® 10 mg/1.5 mL Instructions for Use.
Click here for the Norditropin NordiFlex^® 15 mg/1.5 mL Instructions for Use.
Click here for the Norditropin NordiFlex^® 30 mg/3 mL Instructions for Use.

Parenteral drug products should always be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Norditropin^® MUST NOT BE INJECTED if the solution is cloudy or contains particulate matter. Use it only if it is clear and colorless. Injection sites should always be rotated to avoid lipoatrophy.

References

Norditropin^® cartridges [prescribing information]. Princeton, NJ: Novo Nordisk Inc; 2010.

Indications and Usage:

Norditropin® (somatropin [rDNA origin] injection) is indicated for the treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone, the treatment of pediatric patients with short stature associated with Noonan syndrome or Turner syndrome, the treatment of pediatric patients with short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years, and for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD) who meet either of the following two criteria: 1. Adult Onset: Patients who have GHD, either alone or associated with multiple hormone deficiencies (hypopituitarism), as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or 2. Childhood Onset: Patients who were growth hormone deficient during childhood as a result of congenital, genetic, acquired, or idiopathic causes.

Important Safety Information:

Somatropin should not be used to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure as increased mortality may occur.

Somatropin is contraindicated in patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients. Norditropin® is not indicated for the treatment of patients who have growth failure due to genetically confirmed Prader-Willi syndrome.

Somatropin should not be used or should be discontinued with any evidence of active malignancy. Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Somatropin should be discontinued if there is evidence of recurrent activity. Patients with preexisting tumors or GHD secondary to an intracranial lesion should be monitored routinely for progression or recurrence. In childhood cancer survivors, an increased risk of a second neoplasm, particularly meningiomas in patients treated with radiation to the head for their first neoplasm, has been reported in patients treated with somatropin.

Somatropin should not be used in patients with active proliferative or severe non-proliferative diabetic retinopathy, for growth promotion in pediatric patients with closed epiphyses, or in patients with known hypersensitivity to somatropin or any of its excipients.

Somatropin may decrease insulin sensitivity particularly at higher doses in susceptible patients. Glucose levels should be monitored periodically, including close monitoring of patients with preexisting diabetes or glucose intolerance. New onset of Type 2 Diabetes Mellitus has been reported. Doses of anti-hyperglycemic drugs (insulin, oral, or injectable agents) may require adjustment for patients with diabetes on somatropin therapy.

Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea and/or vomiting, usually occurring within the first eight (8) weeks after initiation of somatropin therapy, has been reported in a small number of patients. In all reported cases, rapid resolution has occurred after therapy cessation or a reduction of dose. Funduscopic examination should be performed routinely before and during somatropin therapy. If papilledema is observed, somatropin treatment should be discontinued.

Fluid retention during somatropin replacement therapy in adults may frequently occur. Clinical manifestations of fluid retention are usually transient and dose dependent.

In patients with GHD, central (secondary) hypothyroidism may first become evident or worsen during somatropin treatment. Periodic thyroid function tests are recommended and thyroid hormone replacement therapy should be initiated or adjusted as needed.

Slipped capital femoral epiphysis may occur more frequently in patients with endocrine disorders (including GHD and Turner syndrome) or with rapid growth. Onset of a limp or complaints of hip or knee pain in somatropin patients should be carefully evaluated. Rapid growth may also result in progression of preexisting scoliosis. Patients with a history of scoliosis or skeletal abnormalities, which may be present in untreated Noonan, Turner or Prader-Willi syndrome, should be monitored.

Patients with Turner Syndrome should be evaluated carefully for otitis media and other ear disorders since these patients have an increased risk of ear and hearing disorders. Somatropin treatment may increase the occurrence of otitis media in patients with Turner syndrome. Somatropin may also increase the risk of IH in Turner patients. In addition, patients with Turner syndrome should be monitored closely for cardiovascular disorders (e.g., stroke, aortic aneurysm/dissection, hypertension) as these patients are also at risk for these conditions.

Congenital heart disease is an inherent component of Noonan syndrome. Though a clinical study in Noonan syndrome reported no evidence of somatropin-induced ventricular hypertrophy or exacerbation of preexisting ventricular hypertrophy (as judged by echocardiography), the safety of Norditropin® in children with Noonan syndrome and significant cardiac disease is not known.

Cases of pancreatitis have been reported rarely in children and adults receiving somatropin treatment, with some evidence supporting a greater risk in children compared with adults. Girls who have Turner syndrome may be at greater risk than other somatropin-treated children. Pancreatitis should be considered in any somatropin-treated patient, especially a child, who develops persistent severe abdominal pain.

Other somatropin-related adverse reactions include injection site reactions/rashes, lipoatrophy and headaches. Subcutaneous injection of somatropin at the same site repeatedly may result in tissue atrophy and can be avoided by rotating the injection site.

Somatropin inhibits 11ß-hydroxysteroid dehydrogenase type 1 (11ßHSD-1) in adipose/hepatic tissue, and may significantly impact the metabolism of cortisol and cortisone. In patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked requiring glucocorticoid replacement therapy. In addition, patients treated with glucocorticoid replacement therapy, especially with cortisone acetate and prednisone, for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses.

Careful monitoring is advisable when somatropin is administered in combination with other drugs known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine) as limited published data suggest somatropin may alter clearance of these compounds.

Because oral estrogen may reduce IGF-1 response to somatropin treatment, girls and women on oral estrogen replacement may require greater doses of somatropin.

The safety and effectiveness of Norditropin® in patients age 65 years and older has not been evaluated in clinical studies. Elderly patients may be more sensitive to the actions of somatropin and may be more prone to develop adverse reactions.

Please click here to view Prescribing Information.